¼«ËÙÁùºÏ²Ê

Skip to main content
Bogdana Schmidt
( out of 176 reviews )

Bogdana Schmidt, MD, MPH

Languages spoken: English, Russian, Spanish, Ukrainian

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
Salt Lake City
801-587-4381

Veterans Administration Medical Center

Salt Lake City
  • Bogdana Schmidt, MD, MPH, is a urologic surgeon at the University of ¼«ËÙÁùºÏ²Ê in Salt Lake City, ¼«ËÙÁùºÏ²Ê. Dr. Schmidt specializes in urologic oncology. She attended University of San Francisco, School of Medicine and stayed to complete her residency training there. She then completed a Society of Urologic Oncology fellowship at Stanford University.

    Dr. Schmidt’s clinical interests include:

    • The treatment of bladder cancer, kidney cancer, prostate cancer, testis cancer, and penile cancer.

    • Novel imaging technologies

    • Organ preservation

    • Minimally invasive/robotic urology procedures.

    Dr. Schmidt’s research interests focus on:

    • Improving patient risk stratification and optimization of surgical outcomes

    • Quality improvement in urologic oncology

    • Addressing health disparities in urologic oncology

    • The integration of artificial intelligence and advanced imaging techniques into urologic care

    Patient Rating

    4.9 /5
    ( out of 176 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 31, 2024
    HUNTSMAN CANCER CENTER

    Excellent physician. Very concerned about your needs and very good about listening and answers questions so that they can be understood. Truly cares about you. Very knowledgeable.

    July 28, 2024
    HUNTSMAN CANCER CENTER

    Dr. Schmidt is extremely knowledgeable, happy, caring, and driven. An exemplary physician in every respect!

    July 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bogdana Schmidt provided the highest quality medical care combined with genuine care for myself and my attending spouse. She listened attentively and patiently, and she is generous with her time and unrushed. All our questions were answered and explanations provided so as to help us reach confident decisions regarding treatment moving forward. In short: Exceptional all around!

    July 17, 2024
    HUNTSMAN CANCER CENTER

    Dr Schmidt explains things in a way that are easily understood.

    July 11, 2024
    HUNTSMAN CANCER CENTER

    Dr. Schmidt gave a thorough explanation of my biopsy results, my treatment options, the potential side effects, and the likely long-term prognosis. She was both informative and compassionate.

    July 11, 2024
    HUNTSMAN CANCER CENTER

    DR. BOGDANA SCHMIDT, MD., IS A WONDERFUL AND VERY SKILLED PROSTRATE CANCER PHYSICIAN AND SURGEON AND IN MY MIND IS A DEFINITE CREDIT TO HERSELF AND THE HUNSTMAN CANCER HOSPITAL. WHAT A TERRIFIC DOCTOR WHO ANSWERED ALL OF MY QUESTIONS RELATIVE TO MY PROSTRATE CANCER AND ALL THE POSSIBLE TREATMENT OPTIONS. AL HEPLER

    July 10, 2024
    HUNTSMAN CANCER CENTER

    Dr. Schmidt is a first class surgeon and I would recommend her to anyone in need of her skills. As a patient, I feel like I am in first class hands.

    July 10, 2024
    HUNTSMAN CANCER CENTER

    As usual, Dr. Schmidt was professional, knowledgeable, and understanding of my needs.

    July 03, 2024
    HUNTSMAN CANCER CENTER

    Yes would recommend Dr Schmidt

  • Bogdana Schmidt, MD, MPH, is a urologic surgeon at the University of ¼«ËÙÁùºÏ²Ê in Salt Lake City, ¼«ËÙÁùºÏ²Ê. Dr. Schmidt specializes in urologic oncology. She attended University of San Francisco, School of Medicine and stayed to complete her residency training there. She then completed a Society of Urologic Oncology fellowship at Stanford University.

    Dr. Schmidt’s clinical interests include:

    • The treatment of bladder cancer, kidney cancer, prostate cancer, testis cancer, and penile cancer.

    • Novel imaging technologies

    • Organ preservation

    • Minimally invasive/robotic urology procedures.

    Dr. Schmidt’s research interests focus on:

    • Improving patient risk stratification and optimization of surgical outcomes

    • Quality improvement in urologic oncology

    • Addressing health disparities in urologic oncology

    • The integration of artificial intelligence and advanced imaging techniques into urologic care

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Urology

    Education history

    Fellowship Urologic Oncology - Stanford University Fellow
    Urologic Surgery - University of California, San Francisco Resident
    Internship General Surgery - University of California, San Francisco Intern
    Medicine - University of California, San Francisco School of Medicine M.D.
    Graduate Training Community Health Science - University of California, Los Angeles M.P.H.
    Physiological Science - University of California, Los Angeles B.S.

    Selected Publications

    Journal Article

    1. Sung D, Schmidt B, Tward JD (2024). The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer. Clin Genitourin Cancer. ()
    2. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. ()
    3. Schmidt B, Velaer KN, Thomas IC, Ganesan C, Song S, Pao AC, Thong AE, Liao JC, Chertow GM, Skinner EC, Leppert JT (2022). Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. Eur Urol Open Sci, 35, 29-36. ()
    4. Vilson FL, Schmidt B, White L, Sorensen SJC, Ganesan C, Pao AC, Enemchukwu E, Chertow GM, Leppert JT (2021). Removing Race from eGFR calculations: Implications for Urologic Care. Urology. ()
    5. Schmidt B, Leppert JT (2021). Costs of Robotic-Assisted Radical Prostatectomy 1 Year After Surgery: Pay Now and Save Later? JAMA Netw Open, 4(3), e212548. ()
    6. Schmidt B, Bhambhvani HP, Greenberg DR, Prado K, Shafer S, Thong A, Gill H, Skinner E, Shah JB (2020). Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter? Urol Oncol. ()
    7. Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR (2018). Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prostate Cancer Prostatic Dis, 22(1), 117-124. ()
    8. Schmidt B, Meng MV, Hampson LA (2018). Operating Room Supply Cost Awareness: A Cross-Sectional Analysis. Urol Pract, 6(2), 73-78. ()
    9. Truesdale MD, Elmer-Dewitt M, Sandri M, Schmidt B, Metzler I, Gadzinski A, Stoller ML, Chi T (2016). Methylene Blue Injection as an Alternative to Antegrade Nephrostography to Assess Urinary Obstruction After Percutaneous Nephrolithotomy. J Endourol, 30(4), 476-82. ()
    10. Schmidt B, Copp HL (2015). Work-up of Pediatric Urinary Tract Infection. Urol Clin North Am, 42(4), 519-26. ()
    11. Kovshilovskaya B, Chi T, Miller J, Stoller ML (2016). Systemic implications of urinary stone disease. Transl Androl Urol, 1(2), 89-96. ()
    12. Weiss DA, Kovshilovskaya B, Breyer BN (2011). Gender trends of urology manuscript authors in the United States: a 35-year progression. J Urol, 187(1), 253-8. ()
    13. Call GB, Olson JM, Chen J, Villarasa N, Ngo KT, Yabroff AM, Cokus S, Pellegrini M, Bibikova E, Bui C, Cespedes A, Chan C, Chan S, Cheema AK, Chhabra A, Chitsazzadeh V, Do MT, Fang QA, Folick A, Goodstein GL, Huang CR, Hung T, Kim E, Kim W, Kim Y, Kohan E, Kuoy E, Kwak R, Lee E, Lee J, Lin H, Liu HC, Moroz T, Prasad T, Prashad SL, Patananan AN, Rangel A, Rosselli D, Sidhu S, Sitz D, Taber CE, Tan J, Topp K, Tran P, Tran QM, Unkovic M, Wells M, Wickland J, Yackle K, Yavari A, Zaretsky JM, Allen CM, Alli L, An J, Anwar A, Arevalo S, Ayoub D, Badal SS, Baghdanian A, Baghdanian AH, Baumann SA, Becerra VN, Chan HJ, Chang AE, Cheng XA, Chin M, Chong F, Crisostomo C, Datta S, Delosreyes A, Diep F, Ekanayake P, Engeln M, Evers E, Farshidi F, Fischer K, Formanes AJ, Gong J, Gupta R, Haas BE, Hahm V, Hsieh M, Hui JZ, Iao ML, Jin SD, Kim AY, Kim LS, King M, Knudsen-Robbins C, Kohanchi D, Kovshilovskaya B, Ku A, Kung RW, Landig ME, Latterman SS, Lauw SS, Lee DS, Lee JS, Lei KC, Leung LL, Lerner R, Lin JY, Lin K, Lim BC, Lui CP, Liu TQ, Luong V, Makshanoff J, Mei AC, Meza M, Mikhaeil YA, Moarefi M, Nguyen LH, Pai SS, Pandya M, Patel AR, Picard PD, Safaee MM, Salame C, Sanchez C, Sanchez N, Seifert CC, Shah A, Shilgevorkyan OH, Singh I, Soma V, Song JJ, Srivastava N, StaAna JL, Sun C, Tan D, Teruya AS, Tikia R, Tran T, Travis EG, Trinh JD, Vo D, Walsh T, Wong RS, Wu K, Wu YW, Yang NX, Yeranosian M, Yu JS, Zhou JJ, Zhu RX, Abrams A, Abramson A, Amado L, Anderson J, Bashour K, Beyer E, Bookatz A, Brewer S, Buu N, Calvillo S, Cao J, Chan A, Chan J, Chang A, Chang D, Chang Y, Chen Y, Choi J, Chou J, Dang P, Datta S, Davarifar A, Deravanesian A, Desai P, Fabrikant J, Farnad S, Fu K, Garcia E, Garrone N, Gasparyan S, Gayda P, Go S, Goffstein C, Gonzalez C, Guirguis M, Hassid R, Hermogeno B, Hong J, Hong A, Hovestreydt L, Hu C, Huff D, Jamshidian F, Jen J, Kahen K, Kao L, Kelley M, Kho T, Kim Y, Kim S, Kirkpatrick B, Langenbacher A, Laxamana S, Lee J, Lee C, Lee SY, Lee TS, Lee T, Lewis G, Lezcano S, Lin P, Luu T, Luu J, Marrs W, Marsh E, Marshall J, Min S, Minasian T, Minye H, Misra A, Morimoto M, Moshfegh Y, Murray J, Nguyen K, Nguyen C, Nodado E 2nd, ODonahue A, Onugha N, Orjiakor N, Padhiar B, Paul E, Pavel-Dinu M, Pavlenko A, Paz E, Phaklides S, Pham L, Poulose P, Powell R, Pusic A, Ramola D, Regalia K, Ribbens M, Rifai B, Saakyan M, Saarikoski P, Segura M, Shadpour F, Shemmassian A, Singh R, Singh V, Skinner E, Solomin D, Soneji K, Spivey K, Stageberg E, Stavchanskiy M, Tekchandani L, Thai L, Thiyanaratnam J, Tong M, Toor A, Tovar S, Trangsrud K, Tsang WY, Uemura M, Vollmer E, Weiss E, Wood D, Wu J, Wu S, Wu W, Xu Q, Yamauchi Y, Yarosh W, Yee L, Yen G, Banerjee U (2007). Genomewide clonal analysis of lethal mutations in the Drosophila melanogaster eye: comparison of the X chromosome and autosomes. Genetics, 177(2), 689-97. ()

    Commentary

    1. Schmidt B, Agarwal N (2021). Black Men Receiving Radiotherapy for Localized Prostate Cancer Have Improved Outcomes-Clinical Trial Access or Racial Advantage? JAMA Netw Open, 4(12), e2140692. ()

    Case Report

    1. Vilson FL, Lin SY, Schmidt B (2020). Resolution of bilateral testicular masses after viral infection. Urol Case Rep, 33, 101388. ()

    Editorial

    1. Bergman J, Schmidt B, Leppert JT (2020). Following Up on an Improperly Drawn Screening Test: The PSA Dilemma. Am J Med, 134(3), e145-e146. ()
  • News & Podcasts